|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatocellular carcinoma in extremely elderly patients:An analysis of clinical characteristics,prognosis and patient survival显示文摘瞄准:80 年或更多与肝细胞癌(HCC ) 识别病人的临床、预示的特征。方法:有 HCC 的 1310 个病人的一个总数在这研究被包括。80 年或更多的 91 个病人在 HCC 的诊断的时候被定义为极其老的组。>
或 = 的 234 个病人 50 年但是不到 60 年被认为是非老的组。结果:两性比率(到女性的男性) 比在非老的组在极其老的组(0.90:1 ) 是显著地更低的(3.9:1, P <
0.001 ) 。为 HBsAg 的积极的率在极其老的组和为显然在极其老的组增加的 HBsAg 和 HCVAb 否定的病人的比例是显著地更低的(P <
0.001 ) 。在下列参数没有有效差量:肿瘤,分级的孩子呸,肿瘤阶段,门静脉血栓形成或腹水的存在,和为 HCVAb 的积极的率的直径和数字。极其老的病人经常没收到外科疗法(P <
0.001 ) 并且他们是更可能的收到保守疗法(P <
0.01 ) 。基于与在二个组之间的全面病人比较的 Kaplan-Meier 方法在幸存曲线没有有效差量。然而,幸存曲线在有阶段 I/II 的极其老的病人是显著地更坏的,上演 I/II,孩子呸分级与非老的组比较的肝硬化。死亡的原因没在病人之中不同,并且大多数盒子甚至在极其老的病人死于肝相关的疾病。结论:在有好肝功能和好表演地位的病人,为 HCC 的好攻击的治疗可能改进幸存率,甚至在极其老的病人。 | Gengo Tsukioka Satoru Kakizaki Naondo Sohara Ken Sato Hitoshi Takagi Hirotaka Arai Takehiko Abe Mitsuo Toyoda Kenji Katakai Akira Kojima Yuichi Yamazaki Toshiyuki Otsuka Yutaka Matsuzaki Fujio Makita Daisuke Kanda Katsuhiko Horiuchi Tetsuya Hamada Mieko Kaneko Hideyuki Suzuki Masatomo Mori | 2006 | World Journal of Gastroenterology2006，12，1： | 7 |
| 2 | MK-0626,a selective DPP-4 inhibitor,attenuates hepatic steatosis in ob/ob mice显示文摘AIM:To investigate the mechanism and in vivo effects of MK-0626,a dipeptidyl peptidase-4 inhibitor,on hepatic steatosis using ob/ob mice.METHODS:We analyzed obese(ob/ob)8-wk-old male mice that had been randomly divided into two groups of ob/ob mice(n=16 each)and were treated with1.5 or 3 mg/kg MK-0626 and two control groups of untreated ob/ob mice and lean littermates(n=16 each).All mice were fed a normal chow diet with or without MK-0626 for either four or eight weeks.Blood samples were collected,and total hepatectomy was performed.RESULTS:The administration of dietary MK-0626 ameliorated the hepatic lipid accumulation in ob/ob micetreated with 3 mg/kg MK-0626(3 MK),P<0.05,vs untreated ob/ob mice(ob/ob).The MK-0626 treatment reduced the serum alanine aminotransferase levels(both treatment groups,P<0.05 vs ob/ob)and glucoses/insulin levels/calculated HOMA scores(1.5 MK,P<0.05vs ob/ob;3 MK,P<0.01 vs ob/ob)and increased the serum adiponectin levels(3 MK,P<0.05 vs ob/ob)in a dose-dependent manner.The MK-0626 treatment increased the m RNA expression of peroxisome proliferator-activated receptorα/microsomal triglyceride transfer protein(1.5 MK,P<0.05 vs ob/ob;3 MK,P<0.01vs ob/ob)but reduced the sterol regulatory element binding transcription factor-1c/fatty acid synthase/stearoyl-Co A desaturase-1(both treatment groups,P<0.01 vs ob/ob).The MK-0626 treatment increased the activity of AMP-activated protein kinase(AMPK)(both treatment groups,P<0.01 vs ob/ob).CONCLUSION:MK-0626 could attenuate hepatic steatosis through enhancing AMPK activity,inhibiting hepatic lipogenic gene expression,enhancing triglyceride secretion from liver and increasing serum adiponectin levels. | Tatsuya Ohyama Ken Sato Yuichi Yamazaki Hiroaki Hashizume Norio Horiguchi Satoru Kakizaki Masatomo Mori Motoyasu Kusano Masanobu Yamada | 2014 | World Journal of Gastroenterology2014，20，43： | 4 |
| 3 | Overexpression of NK2 inhibits liver regeneration after partial hepatectomy in mice显示文摘AIM: To investigate the in vivo effects of NK2 on liver regeneration after partial hepatectomy (PH). METHODS: Survival after PH was observed with 21 NK2 transgenic mice and 23 wild-type (WT) mice over 10 d. Liver regeneration was analyzed using histology and immunohistochemistry. Expressions of genes were analyzed using Northern blot analysis, immunoprecipitation and immunoblotting, and reverse transcriptase polymerase chain reaction assay. KaplanMeier method and the log-rank test were used for ahalyzing the survival after PH. Differences in the resultsof immunohistochemistry and percentage of liver regeneration was determined by the Student's t-test. RESULTS: More than half of NK2 transgenic mice died within 48 h after PH. After PH, increased deposition of small lipid droplets in hepatocytes was evident and hepatic proliferation was inhibited in NK2 transgenic mice. The hepatic expression and kinase activity of HGF receptor, c-Met, were unchanged among WT mice and NK2 transgenic mice after PH. The expression of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in liver tissues were prolonged in NK2 transgenic mice that died after PH.CONCLUSION: Our findings indicate that overexpression of NK2 inhibits liver regeneration after PH. | Toshiyuki Otsuka Norio Horiguchi Daisuke Kanda Takashi Kosone Yuichi Yamazaki Kazuhisa Yuasa Naondo Sohara Satoru Kakizaki Ken Sato Hitoshi Takagi Glenn Merlino Masatomo Mori | 2005 | World Journal of Gastroenterology2005，11，47： | 2 |
| 4 | Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus显示文摘The standard antiviral therapy for dialysis patients infected with hepatitis C virus(HCV) is(pegylated) interferon monotherapy, but its efficacy is insufficient. Oral direct-acting antiviral agents(DAAs) have recently been developed for chronic hepatitis C patients. However, some DAAs have contraindications for chronic renal failure(CRF). Daclatasvir and asunaprevir are metabolized largely in the liver and are not contraindicated in CRF. Combination therapy with daclatasvir and asunaprevir was used for 4 dialysis patients infected with genotype 1b HCV. One patient had viral breakthrough, and the 3 others had sustained virological response 12. One patient was admitted for heart failure and percutaneous coronary intervention due to concomitant ischemic disease. Heart failure was unlikely to be caused by the combination therapy, as it was probably due to water overload. The patient continued to receive the combination therapy after the remission of the heart failure. The combination therapy was well tolerated in the other patients. | Ken Sato Yuichi Yamazaki Tatsuya Ohyama Takeshi Kobayashi Norio Horiguchi Satoru Kakizaki Motoyasu Kusano Masanobu Yamada | 2016 | World Journal of Clinical Cases2016，4，3： | 2 |
| 5 | Non-invasive prediction of non-alcoholic steatohepatitis in Japanese patients with morbid obesity by artificial intelligence using rule extraction technology显示文摘AIM To construct a non-invasive prediction algorithm for predicting non-alcoholic steatohepatitis(NASH), we investigated Japanese morbidly obese patients using artificial intelligence with rule extraction technology.METHODS Consecutive patients who required bariatric surgery underwent a liver biopsy during the operation. Standard clinical, anthropometric, biochemical measurements were used as parameters to predict NASH and were analyzed using rule extraction technology. One hundred and two patients, including 79 NASH and 23 non-NASH patients were analyzed in order to create the predictionmodel, another cohort with 77 patients including 65 NASH and 12 non-NASH patients were analyzed to validate the algorithm.RESULTS Alanine aminotransferase, C-reactive protein, homeostasis model assessment insulin resistance, albumin were extracted as predictors of NASH using a recursive-rule extraction algorithm. When we adopted the extracted rules for the validation cohort using a highly accurate rule extraction algorithm, the predictive accuracy was 79.2%. The positive predictive value, negative predictive value,sensitivity and specificity were 88.9%, 35.7%, 86.2% and 41.7%, respectively.CONCLUSION We successfully generated a useful model for predicting NASH in Japanese morbidly obese patients based on their biochemical profile using a rule extraction algorithm. | Daisuke Uehara Yoichi Hayashi Yosuke Seki Satoru Kakizaki Norio Horiguchi Hiroki Tojima Yuichi Yamazaki Ken Sato Kazuki Yasuda Masanobu Yamada Toshio Uraoka Kazunori Kasama | 2018 | World Journal of Hepatology2018，10，12： | 2 |
| 6 | Nanoparticles in Emissions and Atmospheric Environment: Now and Future显示文摘 | Seishiro Hirano Hiroshi Nitta Yuichi Moriguchi Shinji Kobayashi Yoshinori Kondo Kiyoshi Tanabe Takahiro Kobayashi Shinji Wakamatsu Masatoshi Morita Satoshi Yamazaki | 2003 | Journal of Nanoparticle Research (-)2003，，3： | 1 |
| 7 | Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir显示文摘A 66-year-old, interferon-ineligible, treatment-naive man who was diagnosed with chronic hepatitis C due to hepatitis C virus genotype 1b began combination therapy with daclatasvir and asunaprevir. On day 14 of treatment, hepatic reserve and renal function deterioration was observed, while his transaminase levels were normal. Both daclatasvir and asunaprevir were discontinued on day 18 of treatment, because the patient complained of dark urine and a rash on his trunk and four limbs. After discontinuing antiviral therapy, the abnormal laboratory finding and clinical manifestations gradually improved, without recurrence. Our case fulfilled the diagnostic criteria of probable drug reaction with eosinophilia and systemic symptom(DRESS) syndrome. Despite the 18-d treatment, sustained virological response 12 was achieved. Based on the clinical course, we concluded that there was a clear cause-and-effect relationship between the treatment and adverse events. To our knowledge, this patient represents the first case of probable DRESS syndrome that includes concomitant deterioration of hepatic reserve and renal function due to combination therapy with daclatasvir and asunaprevir, regardless of normalization of transaminase levels. Our case suggests that we should pay attention not only to the transaminase levels but also to allergic symptoms associated with organ involvement during combination therapy with daclatasvir and asunaprevir. | Takayoshi Suga Ken Sato Yuichi Yamazaki Tatsuya Ohyama Norio Horiguchi Satoru Kakizaki Motoyasu Kusano Masanobu Yamada | 2015 | World Journal of Clinical Cases2015，3，12： | 1 |
| 8 | Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19显示文摘Investigational treatments/drugs for coronavirus disease 2019(COVID-19)have been applied,with repurposed or newly developed drugs,and their effectiveness has been evaluated.Some of these drugs may be hepatotoxic,and each monotherapy or combination therapy may increase the risk of drug-induced liver injury(DILI).We should aim to control dysregulation of liver function,as well as the progression of COVID-19,as much as possible.We discussed the potential risks of investigational treatments/drugs and promising drugs for both COVID-19 and DILI due to investigational treatments/drugs. | Ken Sato Yuichi Yamazaki Toshio Uraoka | 2021 | World Journal of Gastroenterology2021，27，48： | 1 |
| 9 | Role of nuclear receptor CAR in carbon tetrachloride-induced hepatotoxicity显示文摘AIM: To investigate the precise roles of CAR in CCl4-induced acute hepatotoxicity.METHODS: To prepare an acute liver injury model, CCl4 was intraperitoneally injected in CAR+/+ and CAR-/- mice.RESULTS: Elevation of serum alanine aminotransferase and extension of centrilobular necrosis were slightly inhibited in CAR-/- mice compared to CAR+/+ mice without PB. Administration of a CAR inducer, PB, revealed that CCl4-induced liver toxicity was partially inhibited in CAR-/- mice compared with CAR+/+ mice. On the other hand,androstanol, an inverse agonist ligand, inhibited hepatotoxicity in CAR+/+ but not in CAR-/- mice. Thus, CAR activation caused CCl4 hepatotoxicity while CAR inhibition resulted in partial protection against CCl4-induced hepatotoxicity.There were no differences in the expression of CYP2E1, the main metabolizing enzyme for CCl4, between CAR+/+ and CAR-/- mice. However, the expression of other CCl4-metabolizing enzymes, such as CYP2B10 and 3A11, was induced by PB in CAR+/+ but not in CAR-/- mice. Although the main pathway of CCl4-induced acute liver injury is mediated by CYP2E1, CAR modulates its pathway via induction of CYP2B10 and 3A11 in the presence of activator or inhibitor.CONCLUSION: The nuclear receptor CAR modulates CCl4-induced liver injury via induction of CCl4-metabolizing enzymes in the presence of an activator. Our results suggest that drugs interacting with nuclear receptors such as PB might play critical roles in drug-induced liver injury or drugdrug interaction even though such drugs themselves are not hepatotoxic. | Yuichi Yamazaki Satoru Kakizaki Norio Horiguchi Hitoshi Takagi Masatomo Mori Masahiko Negishi | 2005 | World Journal of Gastroenterology2005，11，38： | 1 |
| 10 | Primary aldosteronism due to bilateral micronodular hyperplasia and concomitant subclinical Cushing’s syndrome:A case report显示文摘BACKGROUND Adrenal incidentaloma(AI)has been frequently encountered in the clinical setting.It has been shown that primary aldosteronism(PA)or subclinical Cushing’s syndrome(SCS)are the representative causative diseases of AI.However,the coexistence of PA and SCS has been reportedly observed.Recently,we encountered a case of AI,in which PA and SCS coexisted,confirmed by histopathological examinations after a laparoscopic adrenalectomy.We believe that there were some clinical implications in the diagnosis of the present case.CASE SUMMARY A 58-year-old man presented with lower right abdominal pain with a blood pressure of 170/100 mmHg.A subsequent computed tomography scan revealed right ureterolithiasis,which was the cause of right abdominal pain,and right AI measuring 22 mm×25 mm.After the disappearance of right abdominal pain,subsequent endocrinological examinations were performed.Aldosterone-related evaluations,including adrenal venous sampling,revealed the presence of bilateral PA.In addition,several cortisol-related evaluations showed the presence of SCS on the right adrenal adenoma.A laparoscopic right adrenalectomy was then performed.The histopathological examination of the resected right adrenal revealed the presence of a cortisol-producing adenoma,while CYP11B2 immunoreactivity was absent in this adenoma.However,in the adjacent nonneoplastic adrenal,multiple CYP11B2-positive adrenocortical micronodules were detected,showing the presence of aldosterone-producing adrenocortical micronodules.CONCLUSION Careful clinical and pathological examination should be performed when a patient harboring AI presents with concomitant SCS and PA. | Hiroki Teragawa Chikage Oshita Yuichi Orita Kunihiro Hashimoto Hirofumi Nakayama Yuto Yamazaki Hironobu Sasano | 2021 | World Journal of Clinical Cases2021，9，5： | 1 |
| 11 | High-Definition Television System Onboard Lunar Explorer Kaguya (SELENE) and Imaging of the Moon and the Earth显示文摘 | Junichi Yamazaki Seiji Mitsuhashi Masahito Yamauchi Junichi Tachino Rie Honda Motomaro Shirao Kazuo Tanimoto Hiroyuki Tanaka Nobuaki Harajima Asako Omori Satoshi Yahagi Shigehiro Kanayama Yuichi Iijima Hisashi Ohtake | 2010 | Space Science Reviews (-)2010，，1： | 1 |
| 12 | Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling显示文摘BACKGROUND Sodium glucose cotransporter 2(SGLT2)inhibitors are newly developed oral antidiabetic drugs.SGLT2 is primarily expressed in the kidneys and reabsorbs approximately 90%of the glucose filtered by the renal glomeruli.SGLT2 inhibitors lower glucose levels independently of insulin action by facilitating urinary glucose excretion.The SGLT2 inhibitor ipragliflozin has reportedly improved liver steatosis in animal models and clinical studies.However,the mechanisms by which SGLT2 inhibitors improve liver steatosis are not fully understood.AIM To investigate the ameliorative effects of ipragliflozin on liver steatosis and the mechanisms of these effects in obese mice.METHODS We analyzed 8-wk-old male obese(ob/ob)mice that were randomly divided into a group receiving a normal chow diet and a group receiving a normal chow diet supplemented with ipragliflozin(3 mg/kg or 10 mg/kg)for 4 wk.We also analyzed their lean sex-matched littermates receiving a normal chow diet as another control group. Body weight and liver weight were evaluated, and liverhistology, immunoblotting, and reverse transcription-polymerase chain reactionanalyses were performed.RESULTSHepatic lipid accumulation was significantly ameliorated in ob/ob mice treatedwith 10 mg/kg ipragliflozin compared to untreated ob/ob mice irrespective ofbody weight changes. Ipragliflozin had no appreciable effects on hepatic oxidativestress-related gene expression levels or macrophage infiltration, but significantlyreduced hepatic interleukin-1β (IL-1β) mRNA expression levels. Ipragliflozinincreased both the mRNA and protein expression levels of sirtuin 1 (SIRT1) in theliver. The hepatic mRNA levels of peroxisome proliferator-activated receptor γcoactivator 1α (PGC-1α), peroxisome proliferator-activated receptor α (PPARα),and fibroblast growth factor-21 (FGF21) were also significantly higher inipragliflozin-treated ob/ob mice than in untreated ob/ob mice.CONCLUSIONOur study suggests that the liver steatosis-ameliorating effects of ipragliflozin inob/ob mice may be mediated partly by hepatic SIRT1 signaling, possibly throughthe PGC-1α/PPARα-FGF21 pathway. | Takayoshi Suga Ken Sato Tatsuya Ohyama Sho Matsui Takeshi Kobayashi Hiroki Tojima Norio Horiguchi Yuichi Yamazaki Satoru Kakizaki Ayaka Nishikido Takashi Okamura Masanobu Yamada TadahiroKitamura Toshio Uraoka | 2020 | World Journal of Hepatology2020，12，7： | 0 |
| 13 | Extended therapy duration for therapy-refractory hepatitis C patients with genotype 2显示文摘We devised an extended 72-wk peginterferon--2a/ribavirin therapy regimen for the retreatment of highly intractable cases,i.e.,48-wk peginterferon--2b/ribavirin therapy-intractable cases.Although 2 cases achieved a rapid virological response to 72-wk peginterferon--2a/ribavirin therapy,1 case failed to achieve a sustained virological response.Although the reason for this difference in the effectiveness of 72-wk peginterferon--2a/ribavirin therapy between the cases was unclear,the rebound phenomenon of serum transaminase after48-wk peginterferon--2b/ribavirin therapy and the resultant lower viral load compared to that before 48-wk peginterferon--2b/ribavirin therapy might have influenced the treatment outcome.Thus,it may be beneficial to consider the rebound phenomenon of serum transaminase and the changes in viral load resulting from previous interferon-based therapy and then cau-tiously determine the indication and the timing of the administration of 72-wk peginterferon--2a/ribavirin in highly intractable cases.Further studies should be performed to confirm this strategy. | Ken Sato Masatoshi Yanagisawa Hiroaki Hashizume Yuichi Yamazaki Norio Horiguchi Satoru Kakizaki Masatomo Mori | 2013 | World Journal of Gastroenterology2013，19，34： | 0 |
| 14 | Different outcomes of nosocomial infection with hepatitis C virus from the same origin显示文摘有丙肝病毒(HCV ) 的感染的结果在个人之中从自我限制的感染实质地变化到长期的肝炎,肝肝硬化,和肝细胞癌。决定清理或 HCV 的坚持还没被澄清了的机制。这里,我们从一样的起源,但是与相当不同的结果与 HCV 经历了医院相关的感染的二个盒子。一个盒子在尖锐肝炎的一个事件以后解决了,当尽管他们感染一样的起源的 HCV,另外的盒子开发了长期的肝炎时。尽管与一样的起源的病毒感染了,临床并且 virological 功课是完全不同的。这建议主人因素在调节起一个主要作用尖锐 HCV 感染的结果。 | Satoru Kakizaki Hitoshi Takagi Yuichi Yamazaki Naondo Sohara Ken Sato Takeaki Nagamine Masatomo Mori | 2006 | World Journal of Gastroenterology2006，12，4： | 0 |
| 15 | Evaluation study on properties of a macroporous silica-based CMPO extraction resin to be used forminor actinides separation from high level liquid waste显示文摘Basic properties of a silica-based octyl(phenyl)-N,N-diisobutylcarbamoyl-methylphosphine oxide (CMPO) extraction resin (CMPO/SiO2-P) was investigated.Adsorption behavior for some rare earth elements (RE) which are constituents of high level liquid waste (HLLW) and the long-term stability of the extraction resin in nitric acid solution were examined.The CMPO extraction resin was significantly stable in 3 mol·L?1 HNO3 solution at 50oC.Furthermore,the RE(III) were efficiently separated from non-adsorptive fission product (FP) elements such as Sr(II) in a column experiment using a highly nitric acid solution.The separation behaviors of the elements are considered to result from the difference in their adsorption and elution selectivity based on the complex formation with CMPO.There was no strong dependency of RE(III) separation efficiency on feed solution flow rate.Only from the perspectives of the acid-resistant behavior of CMPO extraction resin and the elution kinetics for the metal ions with the extraction resin,the CMPO extraction resin can be used in the modified MAREC process for HLLW partitioning. | LIU Ruiqin WEI Yuezhou Daisuke Tozawa XU Yuanlai Shigekazu Usuda Hiromichi Yamazaki Keizo Ishii Yuichi Sano Yoshikazu Koma | 2011 | Nuclear Science and Techniques2011，22，1： | 0 |
| 16 | Sofosbuvir/Ribavirin therapy for patients experiencing failure of ombitasvir/paritaprevir/ritonavir + ribavirin therapy: Two cases report and review of literature显示文摘BACKGROUND The effectiveness of sofosbuvir/ribavirin(SOF/RBV) combination therapy,which is one of the 1 st-choice therapeutic options for patients with hepatitis C virus(HCV) genotype 2(HCV-G2) in Japan according to the most recent version of the Japan Society of Hepatology guideline, for patients who experienced failure of the ombitasvir/paritaprevir/ritonavir plus ribavirin(OBV/PTV/r+RBV) combination therapy, which was another option for patients with HCV-G2, is unknown.CASE SUMMARY We evaluated the effects of SOF/RBV combination therapy in two patients with genotype 2 a who could not achieve a sustained virological response(SVR) by OBV/PTV/r+RBV combination therapy. One patient was complicated with VogtKoyanagi-Harada(VKH) disease. Resistance-associated variations before SOF/RBV combination therapy were not detected in two patients. Both patients had an SVR at 12 wk after the treatment(SVR12). Regarding adverse events(AEs), itching, chill, a dull feeling in the throat and cough as well as increase of alanine transaminase level were shown in one patient, while a headache and deterioration of light aversion probably due to the recurrence of VKH disease were shown in the other patients. In addition, the latter patient developed arthralgia and morning stiffness approximately 7 wk after the therapy and turned out to be diagnosed with rheumatoid arthralgia.CONCLUSION SOF/RBV therapy might be effective for patients experiencing failure of OBV/PTV/r+RBV therapy, but caution should be taken regarding the AEs. | Ken Sato Yuichi Yamazaki Takeshi Kobayashi Satoshi Takakusagi Norio Horiguchi Satoru Kakizaki Masayasu Andou Yoshihiro Matsuda Toshio Uraoka Hiroshi Ohnishi Hiroaki Okamoto | 2019 | World Journal of Clinical Cases2019，7，9： | 0 |
| 17 | 我在球场卖啤酒显示文摘棒球是日本的国民运动,球场上的运动员是绝对主角,而观众席上售卖零食和啤酒的推销员“啤酒妹”,则是日本棒球比赛中不可或缺的配角。“啤酒妹”可不是一项轻松的工作。一般来说,比赛开始前一小时,“啤酒妹”便会到达球场开始准备工作。等观众陆续进场后,她们就会背着15公斤重的啤酒桶跑遍全场。为了不影响球迷看球,有些“啤酒妹”还会跪下倒酒。 | Yuichi Yamazaki(图) Ami | 2023 | 看世界2023，，13： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员